[go: up one dir, main page]

NO20051074L - Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi - Google Patents

Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi

Info

Publication number
NO20051074L
NO20051074L NO20051074A NO20051074A NO20051074L NO 20051074 L NO20051074 L NO 20051074L NO 20051074 A NO20051074 A NO 20051074A NO 20051074 A NO20051074 A NO 20051074A NO 20051074 L NO20051074 L NO 20051074L
Authority
NO
Norway
Prior art keywords
treatment
diseases
compounds
respond
antiangiogenetic
Prior art date
Application number
NO20051074A
Other languages
English (en)
Inventor
Palle Christophersen
Bjarne H Dahl
Jens Lichtenberg
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of NO20051074L publication Critical patent/NO20051074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Denne oppfinnelsen vedrører anvendelsen av bestemte forbindelser til behandling av sykdommer som gir respons på antiangiogenetisk terapi. For mye angiogenese inntrer ved slike sykdommer som kreft, diabetisk blindhet, aldersrelatert makuløs degenerasjon, revmatoid artritt og psoriasis. Forbindelsene er særlig anvendbare til anti-metastatisk behandling eller til behandling av aldersrelatert makuløs degenerasjon.
NO20051074A 2002-08-01 2005-02-28 Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi NO20051074L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DKPA200300371 2003-03-11
PCT/DK2003/000518 WO2004012733A2 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Publications (1)

Publication Number Publication Date
NO20051074L true NO20051074L (no) 2005-04-29

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051074A NO20051074L (no) 2002-08-01 2005-02-28 Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi

Country Status (17)

Country Link
US (1) US20060058395A1 (no)
EP (1) EP1526851B1 (no)
JP (1) JP2005537336A (no)
KR (1) KR20050026091A (no)
CN (1) CN1671378A (no)
AT (1) ATE372770T1 (no)
AU (1) AU2003260280A1 (no)
BR (1) BR0312929A (no)
CA (1) CA2493253A1 (no)
DE (1) DE60316297T2 (no)
IL (1) IL166040A0 (no)
IS (1) IS7723A (no)
MX (1) MXPA05001235A (no)
NO (1) NO20051074L (no)
NZ (1) NZ537809A (no)
PL (1) PL375318A1 (no)
WO (1) WO2004012733A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527735A (ja) * 2003-06-17 2006-12-07 ノイロサーチ アクティーゼルスカブ ジフェニル尿素誘導体、及びクロライドチャネル遮断剤としてのそれらの使用
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ATE499370T1 (de) 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
WO2006085302A2 (en) * 2005-02-08 2006-08-17 Bmz Diagnosis (2004) Ltd. Composition for treatment of skin disorders
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006017694D1 (de) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
KR20080027890A (ko) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20110110958A1 (en) * 2007-09-11 2011-05-12 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
SI3622953T1 (sl) 2016-05-17 2021-05-31 Scandion Oncology A/S Kombinirano zdravljenje raka
WO2020049139A1 (en) * 2018-09-06 2020-03-12 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
EP0977741B1 (en) * 1997-04-22 2003-09-03 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
HU227711B1 (en) * 1997-12-22 2011-12-28 Bayer Healthcare Llc Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas and pharmaceutical compositions containing them
CN1263733C (zh) * 1998-10-22 2006-07-12 神经研究公司 取代苯基衍生物,它们的制备和用途
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
PL375230A1 (en) * 2002-07-09 2005-11-28 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Also Published As

Publication number Publication date
US20060058395A1 (en) 2006-03-16
JP2005537336A (ja) 2005-12-08
EP1526851A2 (en) 2005-05-04
WO2004012733A3 (en) 2004-03-18
CA2493253A1 (en) 2004-02-12
DE60316297T2 (de) 2008-06-19
NZ537809A (en) 2007-05-31
IL166040A0 (en) 2006-01-15
BR0312929A (pt) 2005-07-12
AU2003260280A1 (en) 2004-02-23
KR20050026091A (ko) 2005-03-14
WO2004012733A9 (en) 2005-03-10
DE60316297D1 (de) 2007-10-25
MXPA05001235A (es) 2005-06-08
IS7723A (is) 2005-03-01
ATE372770T1 (de) 2007-09-15
PL375318A1 (en) 2005-11-28
EP1526851B1 (en) 2007-09-12
CN1671378A (zh) 2005-09-21
WO2004012733A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
NO20051074L (no) Forbindelser som kan anvendes til behandlingen av sykdommer som gir respons pa antiangiogenetisk terapi
TW200736231A (en) Substituted pyrimidines
JOP20220083A1 (ar) حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
NO20051451L (no) Pyrimidinderivater og deres anvendelse som CB2 modulatorer
EA202091709A1 (ru) Ингибиторы днк-пк
WO2004032882A3 (en) Chemical compounds
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
AU2017206631A8 (en) Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
NO20084396L (no) Kombinasjonsterapi
WO2004108139A8 (en) Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
EP4183806A3 (en) Glycan-interacting compounds and methods of use
ATE553122T1 (de) Antiangiogene methoden und zusammensetzungen
DE60318198D1 (de) Tyrosinkinase-hemmer
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EP3674314A3 (en) Apelin polypeptides
WO2004060890A8 (en) 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
MX2020012034A (es) Inhibidores de furina.
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
WO2004069160A3 (en) Chemical compounds
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods